May 25, 2005 — The U.S. Food and Drug Administration and Serono, Inc., have notified healthcare professionals via letter of new information regarding the risks of cardiotoxicity and secondary acute ...
July 6, 2005 — The U.S. Food and Drug Administration (FDA) approved in April revisions to safety labeling to advise that use of mitoxantrone is associated with increased risks of cardiotoxicity and ...
The US Food and Drug Administration and Swiss biotechnology company, Serono, have amended the product label for the latter's multiple sclerosis drug, Novantrone (mitoxantrone), to highlight a risk of ...
Mitoxantrone (Novantrone, OSI) plus corticosteroids relieves pain, but does not prolong survival, of men with metastatic androgen-independent prostate cancer. Phase I/II studies have indicated that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results